| Dabigatran versus warfarin in patients with atrial fibrillation SJ Connolly, MD Ezekowitz, S Yusuf, J Eikelboom, J Oldgren, A Parekh, ... New England journal of medicine 361 (12), 1139-1151, 2009 | 14286 | 2009 |
| Apixaban versus warfarin in patients with atrial fibrillation CB Granger, JH Alexander, JJV McMurray, RD Lopes, EM Hylek, ... New England Journal of Medicine 365 (11), 981-992, 2011 | 10891 | 2011 |
| Apixaban in patients with atrial fibrillation SJ Connolly, J Eikelboom, C Joyner, HC Diener, R Hart, S Golitsyn, ... New England Journal of Medicine 364 (9), 806-817, 2011 | 3314 | 2011 |
| Alirocumab and cardiovascular outcomes after acute coronary syndrome GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ... New England Journal of Medicine 379 (22), 2097-2107, 2018 | 2643 | 2018 |
| Spironolactone for heart failure with preserved ejection fraction B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ... New England Journal of Medicine 370 (15), 1383-1392, 2014 | 2622 | 2014 |
| Lixisenatide in patients with type 2 diabetes and acute coronary syndrome MA Pfeffer, B Claggett, R Diaz, K Dickstein, HC Gerstein, LV Køber, ... New England Journal of Medicine 373 (23), 2247-2257, 2015 | 2504 | 2015 |
| Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2370 | 2017 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2263 | 2019 |
| Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries CK Chow, KK Teo, S Rangarajan, S Islam, R Gupta, A Avezum, ... Jama 310 (9), 959-968, 2013 | 2182 | 2013 |
| Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study MJ O'Donnell, SL Chin, S Rangarajan, D Xavier, L Liu, H Zhang, ... The lancet 388 (10046), 761-775, 2016 | 2157 | 2016 |
| Efficacy and safety of low-dose colchicine after myocardial infarction JC Tardif, S Kouz, DD Waters, OF Bertrand, R Diaz, AP Maggioni, FJ Pinto, ... New England journal of medicine 381 (26), 2497-2505, 2019 | 2114 | 2019 |
| Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study KK Teo, S Ounpuu, S Hawken, MR Pandey, V Valentin, D Hunt, R Diaz, ... The lancet 368 (9536), 647-658, 2006 | 1482 | 2006 |
| Effect of nesiritide in patients with acute decompensated heart failure CM O'Connor, RC Starling, AF Hernandez, PW Armstrong, K Dickstein, ... New England Journal of Medicine 365 (1), 32-43, 2011 | 1442 | 2011 |
| Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort … S Yusuf, P Joseph, S Rangarajan, S Islam, A Mente, P Hystad, M Brauer, ... The Lancet 395 (10226), 795-808, 2020 | 1369 | 2020 |
| Risk factors for myocardial infarction in women and men: insights from the INTERHEART study SS Anand, S Islam, A Rosengren, MG Franzosi, K Steyn, AH Yusufali, ... European heart journal 29 (7), 932-940, 2008 | 1324 | 2008 |
| The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study SA Lear, W Hu, S Rangarajan, D Gasevic, D Leong, R Iqbal, A Casanova, ... The Lancet 390 (10113), 2643-2654, 2017 | 1314 | 2017 |
| Apixaban with antiplatelet therapy after acute coronary syndrome JH Alexander, RD Lopes, S James, R Kilaru, Y He, P Mohan, DL Bhatt, ... New England Journal of Medicine 365 (8), 699-708, 2011 | 1308 | 2011 |
| Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study M Dehghan, A Mente, X Zhang, S Swaminathan, W Li, V Mohan, R Iqbal, ... The Lancet 390 (10107), 2050-2062, 2017 | 1188 | 2017 |
| Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective … S Yusuf, S Islam, CK Chow, S Rangarajan, G Dagenais, R Diaz, R Gupta, ... The Lancet 378 (9798), 1231-1243, 2011 | 1079 | 2011 |
| Cardiovascular risk and events in 17 low-, middle-, and high-income countries S Yusuf, S Rangarajan, K Teo, S Islam, W Li, L Liu, J Bo, Q Lou, F Lu, ... New England Journal of Medicine 371 (9), 818-827, 2014 | 1065 | 2014 |
